Trial Search Results

A Comparative Study of Aleglitazar and Actos in Patients With Type 2 Diabetes Mellitus and New York Heart Association (NYHA) Class II Heart Failure.

This 2 arm study will compare the safety, tolerability and efficacy of aleglitazar and Actos in patients with type 2 diabetes and symptomatic NYHA class II heart failure. Eligible patients will be randomized to receive either aleglitazar, titrated to an individual maximum tolerated dose up to 0.3mg p.o. daily, or Actos, titrated to an individual maximum tolerated dose up to 45mg p.o. daily, in addition to prescribed diabetes therapy where applicable. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Hoffmann-La Roche

Stanford Investigator(s):


  • Drug: Actos
  • Drug: aleglitazar


Phase 2


Inclusion Criteria:

   - adult patients, >=18 years of age;

   - type 2 diabetes for >=1 month;

   - drug naive, or receiving stable doses of <=2 oral antihyperglycemic medications;

   - HbA1c 6.5-10.0% at screening;

   - symptomatic, stable NYHA class 2 heart failure at screening.

Exclusion Criteria:

   - type 1 diabetes;

   - current or previous treatment with insulin;

   - uncontrolled hypertension;

   - NYHA class 1, 3 or 4 at screening.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Debbie Slamowitz
Not Recruiting